December 18, 2024

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN   **Scrip Code: Equity - 500257**

Dear Sir/Madam,

Subject: Confirmation on the news item appearing in Mainstream Media

This is with reference to the captioned subject and new item appeared in Mainstream Media today i.e. on December 18, 2024, titled "Lupin's HIV tablets get FDA nod".

Pursuant to the Regulation 30(11) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to confirm that the Company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg, to market a generic equivalent of Descovy® Tablets, 200 mg/25 mg of Gilead Sciences, Inc. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. This product will be manufactured at Lupin's Nagpur facility in India.

As this event was not material as defined under Regulation 30 of the SEBI Listing Regulations, the same was not disclosed to the Stock Exchanges as required under the said Regulation.

Further, the Company is not aware of any other event or information that was required to be announced and has not been announced in term of the SEBI Listing Regulations. The Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations and shall continue to do so.

You are requested to take the same on your record.

Thanking you,

For LUPIN LIMITED

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICE
(ACS -15754)

LUPIN LIMITED